George Poste

Biography

 Dr. George H. Poste, D.V.M., Ph.D., F.R.C. Path, F.R.S., has been the Chief Executive Officer at Health Technology Networks since 1999. Dr. Poste serves as a Senior Technical Advisor of Caris, Ltd. Dr. Poste is Special Limited Partner at Care Capital, LLC. He also serves as the Chief Scientific Advisor at Caris Life Sciences Inc. He serves as Del E. Webb Chair of Health Innovation at Arizona State University. In February 2009, he assumed the post of Chief Scientist of Complex Adaptive Systems Initiative (CASI) at Arizona State University. He founded the Boidesign Institute at ASU and served with it from 2003 to 2008. In creating this Institute, he designed and built 400,000 sq. ft. of new facilities, achieved cumulative research funding of $225 million and recruited over 60 faculty, including three members of the National Academies of Science and Engineering. From 1992 to 1999, he served as the Chief Science and Technology Officer and President of R&D at SmithKline Beecham Limited (SB). He held other positions at SmithKline Beecham or its related entities. During his tenure at SmithKline Beecham, he was associated with the successful registration of 31 drug, vaccine and diagnostic products. He has been the Non-Executive Chairman of Structural GenomiX, Inc. since 2000. He serves as the Chairman of Scientific Advisory Board at Archemix Corp., and Caris Life Sciences, Inc. He served as Non-Executive Chairman of Caris Molecular Diagnostics since August 2008. He served as Chairman of the Board at SGX Pharmaceuticals, Inc., and Cerebrus Pharmaceuticals Limited. He served as the Chairman of Diadexus, Inc. since September 1997. He served as the Chairman on the Board of Maxygen, Inc. and Illumina Inc. Dr. Poste served as the Chairman of Orchid BioSciences, Inc. (now Cellmark Forensics, Inc.) from 2002 to August 25, 2009. He serves as Vice Chairman at Caris Life Sciences, Inc. He served as Vice Chairman of Miraca Life Sciences, Inc. Dr. Poste has been an Independent Director at Monsanto Company since February 2003. He has been an Independent Director of Exelixis, Inc. since August 2004. He serves as a Director at Caris Life Sciences, Inc. Dr. Poste serves as Member of Scientific Advisory Board at Haplogen GmbH. He serves as a Member of Scientific Advisory Board at Synthetic Genomics, Inc., Anacor Pharmaceuticals, Inc., and Boston BioCom LLC. He serves as Member of the Editorial Advisory Board at RJ Communications and Media Ltd

Research Interest

 Business